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ABSTRACT
Heart valve tissue engineering (HVTE) has the capacity to overcome limitations
in current valve design, enabling the creation of an autologous valve
replacement. We propose that treating radial artery cells (RACs) with a
com bination of growth factors (GFs) may produce cells more sim ilar to valve
interstitial cells (VICs) for HVTE. RACs were treated with combinations of
epiderm al GF (E), basic fibroblast GF (F), platelet-derived GF (P), and
transform ing GF-beta 1 (T). Alpha smooth muscle actin (aSMA) expression was
examined using real time polymerase chain reaction and confocal microscopy. A
reduction in aSMA expression indicated cell transdifferentiation. A combination
of E, F, and P (EFP) decreased aSMA protein and gene expression to
approxim ately 20% and 1% of the controls, respectively. This change was
sustained following 72 hours of GF removal. W e have demonstrated that aSMA
expression in EFP-treated RACs is comparable to levels in VICs, suggesting
these cells may be used for HVTE.

Keywords: aortic valve, valve interstitial cell, heart valve tissue engineering,
radial artery, myofibroblast, smooth muscle cell, alpha smooth muscle actin,
epiderm al growth factor, basic fibroblast growth factor, platelet-derived growth
factor, transform ing growth factor-beta 1
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CHAPTER 1: INTRODUCTION

1.1 The Human Heart and Aortic Valve
The human heart is a highly sophisticated organ that pumps blood throughout the
body. The heart beats at an average frequency o f 100,000 times a day,1,2 which
amounts to approximately 3 billion tim es in the average person’s lifetime.
Com plex machinery within the heart allows it to operate smoothly and mediate
unidirectional blood flow through its four chambers. Four heart valves provide
this coordinated regulation, each valve acting as a gatekeeper to an adjacent
heart cham ber or outflow tract (Figure 1A). Although the four heart valves are
functionally similar, they are structurally distinct. Two atrioventricular valves
divide the atria from the ventricles, while two sem ilunar valves separate the heart
from the pulm onary artery and aorta. Appropriately, the sem ilunar valves are
named the pulmonary and aortic valves. Of the four valves, the aortic valve is
the m ost frequently diseased, likely as a consequence of the high pressures
generated by contractions of the left ventricle. As a result, the aortic valve is the
most com m only studied.

1.1.1 Aortic Cusp Structure
The aortic valve is comprised of three cusps that synchronously open and close
during each cardiac cycle. The three cusps are named the left coronary, the right
coronary, and the non-coronary cusps after their association with the origins of
the two coronary arteries (Figure 1B). Although all three cusps are sim ilar in
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Figure 1. Anatomy of the heart and heart valves. (A) The heart is divided into
four heart chambers, shown here in both frontal and transverse sections. The
atria are separated from the ventricles by two atrioventricular valves, the mitral
and tricuspid valves. These valves are located on the left and right sides o f the
heart, respectively. The sem ilunar valves mediate blood flow from the left and
right ventricles into the major outflow vessels, the aorta and pulmonary artery,
respectively. These valves are appropriately named the aortic and pulmonary
valves. (B) The three cusps that make up the aortic valve are the non-coronary,
left coronary, and right coronary cusps. The base of each cusp is fixed to the
aorta at the aortic root. When the aortic valve is closed, the free edges of all
three cusps are joined (coapt) together. The cusps are connected to one another
at their commissures, where the base of the cusp meets the free edge. Each
cusp exhibits anisotropic properties, differing in the radial and circum ferential
directions. The circum ferential direction courses from commissure to
commissure, while the radial direction runs perpendicularly from the base to free
edge. These figures have been adapted from TrialSight Medical Media © 2009,
Jennifer Kersey E-Porfolio Bio211 Blogspot 2011, Underwood e t at. (2000),3 and
Chelation Therapy Online: A Heart Valve Tutorial © 2008 by Vibrant Life.
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size, the non-coronary cusp tends to have the largest surface diam eter and the
left coronary cusp tends to have the smallest.4 However, the cusps are
functionally and structurally identical. As illustrated, the base of each cusp is
secured to the aorta by a fibrous annulus, referred to as the aortic root. During
valve opening, the cusps open into a cavity superior to the aortic root known as
the aortic sinus. This cavity allows fo r blood to be pumped efficiently throughout
the system ic circulation, while minimizing the biomechanical stress that each
cusp experiences. During valve closing, the large pressures generated in the
aorta force the cusps to come together, closing the valve. The cusps coapt along
their free edge, sealing blood from the inferior left ventricle, and preventing
backflow.

A histological section through the aortic valve cusp reveals the sophisticated
trilam inar organization of the valve extracellular matrix (ECM) (Figure 2A). The
cusp is subdivided into three distinct layers. From inferior to superior, these
layers include the ventricularis, spongiosa, and fibrosa.5 Each of these layers
conveys unique anisotropic behaviour to the aortic valve.6-8 The ventricularis is
dense in radially-oriented elastin fibers, projecting from the aortic root towards
the free edge of the cusp. These fibers largely account for the extensibility of the
valve and facilitate valve recoil during systole. Located at the aortic surface, the
fibrosa is dense in collagen fibers, giving this layer high tensile strength.
Collagen types 1,111 (and to a lesser extent type IV) fibers are arranged
circum ferentially, stretching from commissure to commissure. Interestingly, the
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Figure 2. Aortic valve extracellular matrix (ECM) organization and cell
distribution from development to adulthood. (A) The adult aortic valve is
characterized by a unique trilam inar structure. From the inferior (ventricular)
edge to superior (aortic) surface, the valve is divided into the ventricularis,
spongiosa, and fibrosa, (i) A Movat’s Pentachrome stain shows the collagen
(yellow), elastin (black), glycosaminoglycans (blue), nuclei (dark brown), and
muscle (red) in histological section. The nuclei distributed along the outer
ventricularis and fibrosa are those o f valve endothelial cells (VECs). The
remaining nuclei throughout the cusp prim arily belong to valve interstitial cells
(VICs). Some of the nuclei that colocalize with the red staining may belong to
SMCs. (B) The ECM and VIC distribution in the aortic valve changes over time,
(i) Movat’s Pentachrome stain reveals a homogenous gelatinous structure during
early fetal development (14-19 weeks) that progresses to a bilam inar structure in
late fetal development (20-39 weeks), and eventually a trilam inar structure in
childhood (2-16 years), (ii) A Picrosirius Red stain indicates that collagen fibers
do not become fully oriented until adulthood. Over time, VIC density decreases
and the cells show regional preferences for the ventricularis and fibrosa. These
figures have been adapted from Mendelson and Schoen (2006)9 and Aikawa et
al. (2006).10

6

7
collagen fibers are arranged in a crimped fashion, becoming aligned at higher
pressures.11 This unique property accommodates the extensibility of the
ventricularis without compromising the strength of the fibrosa. Although the
spongiosa is the least studied o f the three valve layers, this layer is thought to
serve a shock-absorbing role between the two more robust layers. A high
density of glycosaminoglycans (GAGs) and proteoglycans in this layer attract
many positively charged ions, which in turn draw in water molecules, giving the
spongiosa its’ absorptive and cushioning function. This exquisite ECM
architecture imparts unique biomechanical properties to the aortic valve.

1.1.2 Valve Interstitial Cells
Specialized populations of cells within the aortic valve maintain valve integrity
and the distinctive ECM arrangement. The aortic valve is prim arily comprised of
three cell types: valve endothelial cells (VECs), valve interstitial cells (VICs), and
a small population of smooth muscle cells (SMCs)12 (Figure 2). VECs are a
heterogeneous population of endothelial cells, continuous with the endocardium
of the heart wall. These cells provide an anti-throm bogenic barrier and facilitate
valve remodeling and repair by transducing extracellular signals to VICs. VICs
are the predominant cell type in the valve,13 and are scattered throughout all
three layers of the valve cusp. These cells maintain the integrity of the valve and
are the prim ary determ inant of valve durability. A prim itive study of VIC biology
by Mulholland and G otlieb14 described these ceils as resembling a fibroblast in
morphology, yet also exhibiting SMC-like features. VICs exhibited two distinct
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phenotypes, prim arily distinguished by differences in cytoplasmic structures,
including the Golgi, ER, and m icrofilam ent organization. The VIC was described
as both contractile and synthetic, a definition that is maintained today.14
Although the complexity of the VIC is still not fully understood, their
heterogeneous and dynamic nature has recently been unveiled.15 VICs can be
sub-characterized into five phenotypes: quiescent (qVICs), activated (aVICs),
em bryonic/progenitor, osteoblastic, and mesenchymal.16 Each VIC phenotype
contributes to the overall valve biology, however, qVICs and aVICs are the major
determ inants of health in the adult aortic valve.

A careful balance between fibroblastic qVICs and myofibroblastic aVICs is
necessary fo r aortic valve hom eostasis.16 Functionally, qVICs are predominantly
synthetic, secreting and maintaining the valve ECM. In contrast, aVICs are
distinguished by their contractile phenotype that enables them to participate in
valve rem odeling, both during development and in the healthy adult valve.15
Valve remodeling is an ongoing process that allows the valve to respond to acute
changes in the valve microenvironment. A useful - and perhaps extreme example o f valve remodeling is valvulogenesis, or valve development.

Aikawa e t a/.10 illustrate the progression o f VIC density and phenotype, as well as
ECM organization in sem ilunar valves from early gestation to adulthood (Figure
2B). From em bryonic development until adulthood, VICs populate the entirety of
the valve cusp. However, the density and distribution of VICs progress from a
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dense and uniform arrangement to one that is sparse and localized, with low
indices of proliferation.17 Furthermore, aVICs largely populate the valve during
developm ent whereas qVICs dom inate the adult semilunar valves. The high
density o f aVICs facilitates remodeling of the embryonic valve, transforming it
from a homogenous gelatinous tissue into the unique trilam inar structure seen in
the adult valve. VICs achieve this metamorphosis by increasing the synthesis of
ECM-modifying proteins, in addition to upregulating proteins that facilitate
m otility, contraction, and adhesion.

The synthesis and secretion o f several matrix metalloproteinases (MMPs) and
tissue inhibitors of matrix m etalloproteinases (TIMPs) - enzymes that degrade
ECM and their inhibitors - are increased during rem odeling.16 Protein levels of
MMP1 (interstitial collagenase) and MMP13 (collagenase 3) are decreased in the
adult sem ilunar valve,10 indicating that levels of MMP expression are correlated
to the degree of valve remodeling. MMP1 specifically targets collagen I, the
prim ary com ponent o f the valve fibrosa, and exhibits a unique expression profile
in response to mechanical loading. MMP1 expression is reduced when the valve
experiences small mechanical strains (allowing for normal valve maintenance),
whereas its expression is increased during mechanical overload, facilitating
intense valve rem odeling.18 VICs in the remodeling valve also express markers
of both cardiac and skeletal muscle, including myosin heavy chain, embryonic
form of smooth muscle myosin heavy chain (smEMB), tropomyosins, and
troponins.19 However, the most recognized marker of the aVIC and thus the
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remodeling VIC phenotype, is the increased expression of the contractile protein
alpha smooth muscle actin (aSMA).

Remodeling is a tightly regulated process that is essential to both valve
developm ent and maintenance. A dysrégulation in remodeling, transpiring from
even a sm all deviation in the qVIC to aVIC equilibrium, can have severe
consequences and lead to valve pathology.

1.2 Aortic Valve Disease
Cardiovascular disease (CVD) continues to be the leading cause of death
worldwide, claiming 30% of all deaths in Canada.20 W hile many form s of CVD
are decreasing in prevalence, one manifestation that continues to increase
despite a growing scientific understanding is aortic valve disease (AVD).21
Problems associated with a diseased aortic valve include obstruction to blood
flow, regurgitation, or both. AVD can stem from a number of causes; two of
which include aortic valve sclerosis (AVS) or inflammatory disease (such as
rheum atic fever or infective endocarditis). AVS features a pathological
accum ulation of lipids and calcific deposits that usually manifests itself in the
elderly population as aortic valve stenosis or regurgitation.22 However, AVS can
also appear prem aturely in patients born with a congenital heart defect, such as
a bicuspid aortic valve.23,24 In contrast, inflammatory diseases of the valve
usually cause a disruption in the ECM fabric, resulting in valvular insufficiency
(regurgitation).
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Both aortic valve stenosis and regurgitation increase the work load of the left
ventricle as more force is needed to project blood throughout the systemic
circuit.25 As the pressures in the left ventricle increase, so do the biomechanical
stresses on the valve cusps. VICs respond to the pathological insult by initiating
valve remodeling, contributing to the cyclical degeneration of the aortic valve. In
mild AVD, several minor surgeries can be performed to alleviate some of the
risks associated with impaired valve function. However, 70% o f all heart valves
requiring intervention cannot be repaired. As a result, over 300,000 patients
worldwide undergo heart valve replacem ent surgery each year,1 13,000 of those
being Canadians.26 Over the next 30 years, this figure is predicted to exceed
more than 1 million cases annually.27 The burden of AVD is evident.
Unfortunately, the detrimental impact of AVD w ill only continue to increase until
pharmacological or surgical intervention is improved.

1.2.1 The Economical and Societal Burden o f A VD
Although the m ortality of AVD is relatively small (approximately 20,000 deaths
annually in the United States),28 the economical and societal burden is severely
underappreciated. Despite an increased understanding in valve biology and risk
factors associated with AVD (and CVD), the number of valve surgeries in
Canada has nearly doubled since 1995.21 Heart valve-related surgeries are the
second most common cardiothoracic procedure and the most common minimally
invasive cardiovascular procedure.2 At a mean cost of $140,000/procedure (in
the United States), this amounts to an estimated annual global economic burden
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of $42 billion.27 This steep figure excludes the costs of hospitalization and lost
productivity o f valve replacement recipients.

Furthermore, the number of valve-related surgeries does not accurately reflect
the incidence in the general population. One in four adults aged 65 or greater
have AVS,29 and although only a fraction of this population will undergo valve
replacem ent surgery, the presence of AVD increases their risk of other CVD by
50% 27 Moreover, in non-W estemized countries, AVD prim arily targets children
and young adults. In the W estern world, AVD is a product of pathological
degeneration,22 whereas in third world countries, AVD typically results from
inflammation and disease. The younger populations are essential to sustain
development, and the high incidence of AVD threatens economic advancement
in these nations. It is evident that the incidence and global impact of AVD is
largely underrepresented, and the need for superior understanding of aortic valve
pathology, treatm ent and methods o f intervention are required.

1.2.2 Cellular Etiology of AVD
Studies identifying the cellular pathways involved in the etiology of valve
pathology are in their infancy. Butcher (2011) describes several cells and
pathways that may be implicated in valve disease, some of which include
dysfunctional endothelial cells, VIC activation, matrix remodeling, lipid
metabolism, serotonin metabolism, osteogenic differentiation; or abnormal
signaling pathways including Notch, endothelial nitric oxide synthase or W nt.27
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The histological examination of diseased valves has revealed several cellular
features that are associated with valve pathology.17,30 Diseased pediatric aortic
valves provide a unique opportunity to study AVD in the absence of age,
hypercholesterolem ia, and hypertension.17 These diseased valves exhibit ECM
accum ulation, and a disruption in collagen and elastin fiber organization, as well
as fiber fragm entation. Also, VICs were predominantly o f the aVIC phenotype
and localized into cell clusters, leaving some valve areas relatively cell-free.2 In
myxomatous mitral valves, sim ilar ECM disorganization is observed; the valves
exhibited diminished collagen fiber density, fiber disorganization, and elastic fiber
fragm entation.30 Interestingly, the fragmented fibers and loose ECM colocalize
with the remodeling protein aSMA. These valves also exhibit increased MMP13
and SMemb staining in histological section, paired with an abnormal distribution
o f vim entin.10,30 These findings indicate the importance of tight regulation of
valve rem odeling, and how increased expression o f aSMA correlates with a
disruption in tissue homeostasis. Further studies are necessary to elucidate
founding mechanisms in valve pathology in order to better develop treatments
and therapeutic approaches.

1.3 Current Valve Replacements
Patients undergoing aortic valve surgery are currently presented with three
replacement options: a mechanical valve, a bioprosthetic or tissue valve, or an
allograft or autograft (Figure 3). Each valve offers benefits over its counterparts,
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Figure 3. C urrent valve replacem ents. (A) The St. Jude Medical mechanical
valve (Medtronic) is the most popularly implanted mechanical valve in the United
States, implanted in over 1.9 million patients worldwide to date. This bileaflet
mechanical valve was originally fabricated from a sewing ring (stent), and the
leaflets from Pyrolite carbon. The central hinge of this valve provides a greater
orifice opening area, allowing for improved hemodynamics. (B) The CarpentierEdwards PERI MOUNT Magna Ease aortic heart valve is a bioprosthetic or tissue
valve. This valve is comprised of three leaflets fabricated from decellularized
bovine pericardium, attached to a stent or sewing ring. These valves have
shown relatively favourable results, providing over 20 years o f durability.31
(C) The illustration of the Ross Procedure (i-iii) depicts an exchange of the
defective aortic valve and a small portion of aorta for the autologous pulmonary
valve and matching piece o f pulmonary artery (pulmonary autograft). The
pulmonary valve and pulmonary artery must then be replaced with another valve
replacement and arterial conduit (iii). The left coronary (LCA) and right coronary
(RCA) arteries provide a visual reference for this procedure. In the instance of
an allograft, the same highlighted portion of the aortic valve (i) would be
dissected from a cadaver and placed in the equivalent aortic position of the
patient. These figures have been adapted from Medtronic © 2011, Edwards
Lifesciences © 2011, and the University of Southern California Keck School of
Medicine: The Ross Procedure © Department o f Cardiothoracic Surgery.
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yet each are also plagued with side effects that negatively impact the patient’s
quality o f life.

1.3.1 Mechanical Valve
Mechanical heart valves (Figure 3A) made their clinical debut in 1952, when Dr.
Charles Hufnagel implanted a caged ball valve in a patient suffering from AVD.32
Since then, the field has evolved drastically. Improved biomaterial selection and
structural design of both the valve stents and ‘leaflets’, have enhanced the
hemodynamic properties of valve conduits. These valves offer a durable option
for patients with a reduced risk of valve failure.33 However, the foreign nature of
the mechanical valve maintains its thrombogenic and thromboembolic potential.
As a result, recipients of mechanical valves are required to undergo lifelong
anticoagulant therapy, increasing the risk of hemorrhage and severe bleeding
incidents.33 Furthermore, mechanical valves have no capacity for growth in the
patient. This caveat drastically increases the risk of m ortality in the pediatric
population with each subsequent surgery.

1.3.2 Bioprosthetic Valve
Bioprosthetic valves (Figure 3B) are derived from xenogenic tissue that has been
cross-linked and decellularized to minimize conduit immunogenicity. Sources for
the xenogenic conduits are namely porcine heart valves or bovine pericardium.
The first clinical use of a tissue valve was in 1956,34 not long after the first
mechanical valve transplant. Dr. Gordon Murray was the first to document
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implanting a human cadaveric aortic homograft into the thoracic aorta of a patient
suffering from valvular insufficiency.34 Over the next 20 years, xenogenic
bioprosthetic valve engineering improved greatly. The use of bioprosthetic
valves instead of cadaveric allografts eliminated com plications such as valve
variability, storage, immunogenicity, sizing, and availability. Unlike its
m echanical counterpart, bioprosthetic valves offer a hemocompatible and
hemodynamic alternative,35,36 freeing the patient from the daily use of
anticoagulant therapy. However, bioprosthetic valve transplants have
dem onstrated limited durability, fatigue and ultim ately tissue failure, often
requiring subsequent valve replacem ent in 10-15 years.33' 36

1.3.3 Allograft and Autograft
An allograft or homograft describes an aortic valve that has been taken from a
human donor. Autografts (Figure 3C) are pulmonary valves that are relocated to
the aortic position in the same patient, a procedure named after Dr. Donald Ross
who first proposed the technique in 1962.37 The allograft and autograft benefit
the patient by maintaining the three-dimensional ECM valve architecture that is
necessary for normal valve function and biomechanics. The Ross procedure has
the additional benefit of elim inating potential complications associated with
immune rejection as the valve is derived from an autologous source. These
procedures yield relatively promising results, showing freedom from autograft
and homograft failure at 94.1% ± 5.7% and 96.6% ± 3.4% at 5 years,
respectively.38 However, complications do exist. Allografts are limited by valve
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availability and immune tolerance. In addition, slight disagreement in valve
thickness, diam eter and ECM organization exist between the aortic valves o f two
individuals, as well as the pulmonary and aortic valves in the same individual.10
These variances may potentially lead to difficulties with the donor valves.
Furthermore, patients who opt for the Ross procedure are required to undergo
two valve surgeries. Although these valve models allow fo r some growth within
the patient, alternative approaches to valve replacement need to be investigated.

Heart valve replacement strategies have evolved immensely since they were first
introduced over 50 years ago.32 Currently, valve models offer durability,
hemocompatability, or immune tolerance; however, these features have yet to be
combined into one valve model. Tissue engineered heart valves (TEHV) seem to
offer the greatest potential in optimizing patient outcomes. TEHV have the
capacity to grow, adapt, and remodel, answering the largely unmet needs of
current pediatric patients.39 A bioprosthetic heart valve derived from an
autologous cell source may provide a solution to the lim itations of current valve
conduits.

1.4 Tissue Engineered Heart Valves (TEHV)
Tissue engineering, once thought to be a futuristic concept,40 has since
revolutionized the field of organ transplantation. Tissue engineering is described
as ‘an interdisciplinary field that applies principles of engineering and the life
sciences toward the development o f biological substitutes that restore, maintain,
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and improve the function o f damaged tissues and organs’.40-42 The applications
of tissue engineering are lim itless and have already been applied to the
epithelial, genitourinary, and vascular systems, as well as applications in bone,
cartilage, liver, and the heart valves.40,43 In April 1998, the potential of tissue
engineering became realized as Vacanti’s ‘Earmouse’ publically made BBC
News headlines.

Dr. Charles Vacanti and colleagues implanted a biodegradable

ear-shaped scaffold pre-seeded with bovine chondrocytes into the subdermal
dorsum o f a nude mouse, allowing fo r vascularization of the cell-scaffold
construct (CSC). Other tissue engineering successes have been attained in the
regeneration o f skin and bone. Unfortunately, success in cardiac tissue
engineering has not been as immediate. The regeneration of a fully functional
heart in vitro was originally predicted to take a mere 10 years.44 However,
cardiac tissue engineering has experienced many difficulties in recreating the
com plexity and sophistication of this organ and its associated structures.

Like other ventures in tissue engineering, the heart valve tissue engineering
(HVTE) paradigm appears simple yet offers a much more complex challenge. In
brief, HVTE can be summarized into five steps: (1) cell isolation, (2) in vitro
expansion, (3) scaffold seeding, (4) conditioning, and (5) implantation (Figure 4).
However, this deceivingly simple model has offered challenges at every available
opportunity, mostly in trying to identify which cell type, scaffold, and conditioning
protocols will promote the development of an acceptable TEHV. The ideal cell

F igure 4. H eart valve tis s u e en gine erin g (HVTE) paradigm . (1) Autologous
cells are harvested from some location in the body and (2) cultured in vitro. Both
valve interstitial cell (VIC) and valve endothelial cell (VEC) surrogate populations
need to be generated. (3) The cells are seeded on to a scaffold material, a
structure that provides a temporary biomechanical fram ework for the cells. (4)
The cell-scaffold construct (CSC) undergoes various in vitro conditioning
protocols, often in a pulse duplicator (‘bioreactor’) system. Some of these
biomechanical stim uli may include simulating shear stresses (blood flow), flexure
(bending o f valve), and mechanical loading (back pressure) that the valve
experiences in vivo. (5) The conditioned CSC is then implanted in vivo into an
FDA-approved animal model. This figure has been adapted from Vis et al.
(2011).45
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type would be easily accessible and sufficient in number, and adequately mimic
the functional heterogeneity of VICs. The scaffold material would act as a
tem porary and durable reservoir fo r cells, eventually being resorbed as the cells
produce their own ECM. The CSC would then be subjected to the ideal
combination of conditioning protocols, likely mimicking the natural biomechanical
profile o f the aortic valve environment. Following the identification of these three
key elem ents, the conditioned CSC would then be implanted into the ideal animal
model (currently, the sheep is the only model that is FDA-approved). The
process is complex and the ideal valve model has yet to be elucidated.
However, an increased understanding of the valve development, biology, and
m icroenvironm ent has helped to guide future directions in HVTE.

1.4.1 Cell Type
Many cell types have been employed for HVTE, yet a cell type that adopts the
diverse functions of the VIC to an acceptable standard has yet to be identified.
Initially, m yofibroblasts and endothelial cells harvested from an artery were the
cells o f choice for generating TEHV. The use of ovine myofibroblasts and
endothelial cells was demonstrated in an in vivo lamb model.46 Cells were
harvested from the ovine carotid artery and seeded on to a nonwoven
polyglycolic acid (PGA) mesh scaffold. CSCs were cultured in a pulse duplicator
system (‘bioreactor') for 14 days prior to implantation in the pulmonary positions
of the lambs fo r up to 20 weeks. Echocardiography confirmed healthy function of
the TEHV in vivo, while histological analysis revealed a trilam inar structure
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consistent with the native valve. Twenty-week old explants exhibited mechanical
properties and an ECM composition that reflected values found in native valves.
This study confirms that a valve grown in vitro can meet in vivo demands in the
pulm onary position. However, the tensile strength and ECM organization of this
TEHV does not meet the high pressure requirements of native aortic valves.

Stem cells are another cell type studied for HVTE, due to their pluripotent and
autologous nature. These cells may be derived from an adult organ, or the stem
cell-rich umbilical cord of a newborn. Bone marrow-derived stem cells (BMSCs)
and adipose-derived stem cells (ASCs) provide two different adult cell sources
that have been investigated for HVTE.47'49 Scaffolds seeded with BMSCs show
promising results both in vitro and in vivo. Using a biomimetic environment,
BMSC CSCs produced viable tissue and formed ECM. The cells were synthetic
and m yofibroblastic, forming a homogenous valve-like tissue with mechanical
properties comparable to the native valve.50 In vivo, BMSCs formed a stratified
ECM after 8 months o f implantation in a lamb.47 Echocardiographic evaluation
revealed only trivial to mild regurgitation in these animals. Although clinically
feasible, stem cells from bone marrow only represent a fraction of the total
number of the cells in bone marrow, and their vitality decreases with age.51

Conversely, ASCs represent another population of stem cells that are easily
isolated during abdominal liposuction. These cells are collected at sufficient
densities, eliminating the need for in vitro expansion.48 When seeded on to a
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collagen scaffold and exposed to 14% stretch over three days, these cells
increased DNA and ECM synthesis. Interestingly, gene expression for collagen
III (a key indicator of valve rem odeling) was upregulated in these cells. Collagen
and elastin production and cross-linking were also increased. These results
inspire future HVTE efforts using ASCs, however, the ease o f accessing these
cells in all age groups as well as their in vivo potential needs to be assessed.

Umbilical cord stem cells (UCSCs) present another viable cell source for
pediatric HVTE.52"55 Dynamic conditioning of UCSCs promotes cell infiltration
and collagen production, although the mechanical profile of these CSCs remains
im m ature.55 Cord blood containing UCSCs can be easily harvested following
birth in parents who elect to do so. Intrauterine echocardiography during
pregnancy facilitates the early detection of cardiac birth defects, allowing parents
to prepare for this decision.

Healthcord, a Canadian-run cord blood bank, will

cryopreserve cord blood at a lowest per unit price of $2450 for 18 years.56
Although the cryopreservation techniques that these companies employ are not
fully disclosed, many studies confirm rapid decreases in cell viability while frozen.
Furthermore, UCSCs only present a viable option for infants, children, and
potentially young adults. This cell therapy excludes the elderly population and
thus the m ajority of Canadian heart valve replacement recipients. Currently, no
cell type has been identified that is easily accessible, sufficient in number,
available to all age groups, and produces an ECM profile sim ilar to that observed
in the native valve.
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1.4.2 Scaffolds
In tissue engineering, a scaffold describes any structure that supports the cells
and provides a temporary biomechanical fram ework.43 The scaffold must be
durable enough to support the growth o f the cells, yet it must also be degradable
as the cells eventually replace it with their own ECM. Identifying a scaffold that
serves all o f these functions is a challenging task for HVTE. Currently, two main
genres o f scaffolds exist: acellular matrix xenografts or bioresorbable scaffolds.1
Acellular m atrix xenografts are typically porcine valves that have been
crosslinked with gluteraldehyde (to reduce the immunogenicity of the implant).
The decellularized xenograft provides a vacant ECM template in a comparable
human valve architecture4 that allows for the cells to repopulate it, either prior to
or following implantation. CryoLife, an international organization for implantable
cardiac biom aterials, brought this technique into clinical practice in Europe using
the valve Synergraft®. Unfortunately, the clinical trials ended in disaster, killing
three out o f four patients as early as one week following im plantation.57 The
valves showed marked inflammation, fibrosis, and cusp deterioration. These
adverse results suggest alternative HVTE scaffold methods must be investigated.

Bioresorbable scaffolds are a more widely used technique in HVTE, and have
been employed for the tissue engineering of other living tissues as well.
Bioresorbale scaffolds are porous, allowing the cells to infiltrate the scaffold
material. These scaffolds are of natural and/or synthetic origin. One
comm ercially available natural scaffold is porcine small intestinal submucosa
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(SIS), a tissue that is widely used in skin wound repair because of its ability to
both recruit cells into the new tissue and be resorbed by them. However, a
compromise o f natural scaffolds is their limited durability. Synthetic scaffolds
traditionally include polylactic acid (PLA) and PGA, however, these woven
polymers provide a framework that is too durable and not resorbed well. In
addition, some investigators have experienced difficulty getting cells to adhere to
these polymers. Further studies are being conducted to identify equally durable
substances that are both resorbable and adherent for cells. W hether an acellular
xenograft or a bioresorbable scaffold, identifying the ideal scaffold is necessary
to the development of a fully functional TEHV.

1.4.3 Conditioning
Biomechanical conditioning adopts a biomimetic paradigm, aiming to simulate
the native biomechanical stimuli in the aortic heart valve environment. These
include generating forces that mimic the shear stresses (blood flow), flexure
(bending o f valve), and mechanical loading (back pressure) that the valve
experiences2. The benefits of both in vitro and in vivo biomechanical
conditioning on ECM production and organization are well characterized,18,58,59
and have been previously introduced in Section 1.4.1. Figure 5A shows two
TEHV, generated using static or dynam ic conditions. Ovine myofibroblasts
seeded on pre-molded scaffolds were subjected to gradually increasing flow and
pressure conditions in a bioreactor for 14 days. Dynamically cultured conduits
exhibited dense tissue form ation at the surface, and a looser arrangement in the
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Figure 5. T h e benefits o f in vitro and in vivo d yn am ic co n dition in g on
ex tra ce llu la r m atrix (EC M ) o rg an izatio n . Ovine m yofibroblasts isolated from

the carotid artery were seeded on to bioresorbable trileaflet valve scaffolds, and
overlaid with autologous endothelial cells, form ing cell-scaffold constructs
(CSCs). (A) The CSCs were cultured for 14 days in either (i) static conditions
(magnification *100) or (ii) a pulse duplicator system with gradually increasing
flow and pressure gradients (magnification *20). Visualized using a hematoxylin
and eosin stain, dynam ically conditioning the CSCs promoted increased ECM
organization. (B) The dynam ically cultured CSCs were implanted in lambs for up
to 20 weeks. Hematoxylin and eosin staining reveal increasing tissue
organization from (i) 6 weeks (magnification *50) to (ii) 16 weeks (magnification
*100). (iii) Movat’s pentachrome staining reveals a prelim inary trilam inar
structure (magnification *100) at 20 weeks. These explants show collagen
(yellow), glycosaminoglycans (blue), and elastin (black) staining. The arrow
indicates the inflow or ventricular surface of the explanted CSC. These figures
have been adapted from Hoerstrup et al. 2000.46

28

In Vitro

(i) Static culture (14 days)

(ii) Dynamic culture (14 days)
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centre. These TEHV stained positively for collagen and GAGs, and
demonstrated a much more highly organized ECM overall in comparison to the
static controls. Dynamically cultured TEHV showed stress-strain relationships
comparable to native valves, indicating the role of stretch in shaping valve
architecture. No differences in tissue formation were observed at 21 or 28 days
of treatm ent, suggesting that 14 days is sufficient for ECM organization.

Furthermore, implantation of these dynam ically cultured TEHV into lambs for up
to 5 m onths promoted prelim inary ECM stratification (Figure 5B). Valve conduit
pliability increased over tim e which indicates that the myofibroblasts were able to
resorb the scaffold material, replacing it with their own ECM. Unlike in vitro
culture systems, the in vivo valve environment supplies anisotropic (unequal)
back pressure, hemodynamic flow, and cyclic valve flexure; in addition to
supporting the interaction of host cells with the TEHV. Together, these studies
along with many others highlight the importance of a HVTE paradigm that
accurately mimics in vivo conditions using biomechanical conditioning.

1.4.4 The Future of HVTE
The creation of an autologous valve that grows with the patient, actively
responds to injury, and adapts to changes in the valve microenvironment has
enormous therapeutic potential. Patients of all ages could benefit from a TEHV,
eliminating side effects that are partnered to current models. The last 20 years
o f HVTE have focused on developing a greater understanding of aortic valve
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biology, development and biomechanics, allowing a definition o f the HVTE
paradigm to be established. Simulating in vivo valvulogenesis and the valve
environm ent in vitro have become the gold standard for HVTE. The future of
HVTE lies in fully recreating the developing valve, with careful consideration as to
what cell type, scaffold, and conditioning protocols are employed. The next
developm ent in HVTE requires the cell selection to be revisited, in order to
properly identify a cell source that im itates the functional and phenotypic
heterogeneity of the VIC.

1.5 Rationale
Cells selected for HVTE must be both synthetic and contractile, mirroring the
predom inantly dual nature o f VICs in the adult aortic valve. Originally, the
m yofibroblast was used for HVTE based on the commonalities it shares with
aVICs: Both cell types are highly contractile and express aSMA. Similarly, SMCs
share many characteristics with VICs. Porcine aortic SMCs contrasted with
porcine aortic VICs show sim ilar morphological and phenotypic features in both
two-dim ensional (2D) and three-dim ensional (3D) culture.60 Both cell types show
reduced aSMA protein expression in a 3D model, and contract collagen gels at
sim ilar rates. The sim ilarities between SMCs and VICs - more specifically
between SMCs and aVICs - suggest SMCs as a candidate cell type for HVTE.
However, the ideal population of SMCs needs to be both easily accessible and
transform able into a more synthetic and proliferative qVIC-like cell.
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One cell source that has been proposed for HVTE is the radial artery.61 Located
in the forearm , the radial artery along with the ulnar artery carries oxygenated
blood through the forearm to the hand. The network formed by these two
vessels provides a redundant blood supply to the hand, so that oxygenation of
the forearm and hand would not be jeopardized in the event that either vessel
becomes compromised. This unique feature has already been exploited clinically
for the use of coronary artery bypass grafting.

The radial artery provides an abundant source o f both SMCs and endothelial
cells, two populations that w ill be useful in HVTE. The radial artery is organized
into three layers: the tunica intima, the tunica media, and the tunica externa. A
heterogeneous population of radial artery smooth muscle cells (RACs) isolated
from the tunica media have already been characterized.61 Immunohistochemically, the radial artery stains positively fo r SMC markers aSMA and
smoothelin. CD90 (fibroblast surface antigen) and h-caldesmon (a calmodulin
binding protein) expression vary depending on in vitro culture media. For the
purpose of HVTE, aSMA expression in RACs is too high. The contractile
apparatus in these cells needs to be manipulated so that aSMA content is
reduced. It is possible that transform ed RACs may provide a more suitable,
autologous HVTE cell source.

One method to manipulate phenotypic expression in vivo that can be exploited in
vitro for HVTE is the use of biochemical stimuli such as growth factors (GFs).
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GFs are typically proteins or steroids that act as signaling molecules on both
local and distant targets. GFs interact with internal or external cell receptors,
triggering intracellular cascades that converge on modifying gene expression and
ultim ately protein expression. Often, these signaling molecules modify cell
growth, proliferation, and/or differentiation. Several studies have indicated the
responsiveness of SMCs to various GFs.62 These findings suggest that with the
appropriate combination of GFs and culture conditions, it may be possible to
transdifferentiate RACs into a synthetic phenotype, characterized by a reduction
in aSMA expression.

The GF pathways involved during valvulogenesis may provide a template for GF
selection. Combining GFs in vitro that are critical to valve development as well
as adult valve remodeling may direct the phenotypic development of RACs in a
sim ilar fashion as VIC precursor cells. For our model, four GFs have been
selected: epiderm al growth factor (EGF), basic fibroblast growth factor (bFGF),
platelet-derived growth factor (PDGF), and transforming growth factor-beta 1
(TGF-|31). To understand the roles o f these factors, a brief introduction into valve
developm ent must be provided.

The heart and its accessory structures are formed from a primordial heart
tube.2,17,63'65 The wall of the heart tube consists of an inner endocardium and an
outer myocardium that sandwiches a layer of ECM, referred to as the cardiac
jelly. After heart tube looping, the sites where the atrioventricular and semilunar
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valves w ill eventually form swell into accumulations of ECM, known as cardiac
cushions. The cardiac cushions are formed by endocardial cells delaminating
from the endocardium and invading the cardiac je lly at day 35 of gestation.18 The
invading cells develop into mesenchymal cells (VIC precursors) by a process
termed endothelial-mesenchymal transition (EMT). The cushions eventually
protrude from the heart tube wall, form ing thin, gelatinous valve precursors.
EGF and the EGF receptor (EGFR) fam ily have been implicated in the formation
o f a healthy, thin, fibrous valve.66 Studies altering the activity of the intracellular
kinase domain of the receptor tyrosine kinase (RTK) EGFR in mice lead to valve
hyperplasia, characterized by an accumulation of mesenchymal cells in the
ECM.65 These studies suggest that EGF and EGFRs help guide the late stages
of EMT.

Members of the fiboblast growth factor (FGF) fam ily are critical to the proliferative
expansion o f mesenchymal cells in the embryonic sem ilunar valve.67 Transcripts
for FGF receptors (FGFRs), which are also RTKs, have been identified pre- and
post-EMT, suggesting their importance in this process. bFGF also contributes to
the regulation of vascular endothelial growth factor (VEGF) expression in the
developing valve.65 VEGF is a critical m odulator of cusp formation, exhibiting a
restricted expression profile that is thought to pre-pattern the location of valve
form ation.68 Furthermore, bFGF enhances VIC wound repair in the adult valve,13
a process that shares many sim ilarities with valve remodeling during
development. In cultured VICs, bFGF blocks TGF-|31-directed myofibroblast

34
activation by repressing Smad (a fam ily of intracellular transcription factors)
activity.69 This suggests that bFGF favours the fibroblastic qVIC phenotype that
is desired for HVTE. bFGF has already been applied to HVTE, generating
increased tissue formation in CSCs.49

PDGF and PDGF receptors (PDGFRs) are also critical to cardiac
developm ent.70'71 In vitro, PDGF directs the migration of valve endothelial cells,
promoting a mesenchymal transition. In human pulmonary valve endothelial
cells from a 9 month old child, PDGF reduced both CD31 (endothelial cell
m arker) and aSMA expression,72 supporting the acquisition of a mesenchymal
phenotype. Furthermore, 100% of mice deficient in PDGF or PDGFR genes
exhibit underdeveloped valves.73 Valves from these mice were short, thick, and
cushion-like, failing to develop into thin fibrous structures. This finding supports
the regulation o f endothelial cell migration by PDGF, strengthening the role of
PDGF signaling in EMT.74

TGF-J31 is a homodimeric protein that interacts with the TGF-J3 receptors, which
are serine-threonine kinases. Growing evidence implicates the TGF-J3
superfam ily and related bone morphogenetic proteins in the regulation of valve
development and EMT.64,66,75 In the murine embryo, TGF-(31 RNA is increased
in endocardial cells overlying the cardiac cushion, and persists in the valve
endothelial cells post-partum .75 The presence of endoglin (a glycoprotein that
complexes with the TGF-J31 receptor) on human endocardial tissue mesenchyme
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during heart septation, valve form ation and m aturation,76 stresses the importance
of TGF-p1 in modulating valve development through interactions with the
endocardium. T G F -pi is also able to stim ulate an EMT-like process in cultured
adult VECs, causing mature endothelial cells to adopt a more mesenchymal
phenotype, characterized by an increase in aSMA.77 This may be one
mechanism by which VICs are replenished in the mature valve.77

The stim ulatory effects of TG F -pi on aSMA expression and acquisition of the
m yofibroblast phenotype have been characterized in many cell types.78,79' 80
TG F-pi-m ediated increases in this contractile protein stimulate valve remodeling
by aVICs. However, one study found that T G F -pi in combination with both EGF
and PDGF could have opposite effects.81 This triple GF therapy reduced aSMA
in rat aortic SMCs, indicating that GFs act on cells in a coordinated fashion and
can alter the cells differently than any factor could alone.

The interaction of EGF, bFGF, PDGF, and/or T G F -pi helps to regulate both
valve developm ent and healthy adult valve remodeling.66 The collaborative effect
that these four GFs may have on RACs to promote a fibroblastic and synthetic
qVIC phenotype needs to be examined. Recreating valve development using
GFs is consistent with the biom imetic HVTE paradigm, potentially enabling the
identification o f an ideal cell type for HVTE.
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1.6 Objectives
The objectives of this thesis are:
1. To examine whether the viability o f RACs becomes compromised with
increasing concentrations o f EGF, bFGF, PDGF, or TGF-01.
2. To assess if combinations of EGF, bFGF, PDGF, and/or TGF-31 can
reduce aSMA expression in RACs. Out of the 15 possible combinations of
one, two, three, or four GFs, one ‘ideal’ combination may be identified that
causes RACs to develop a more qVIC-like phenotype (characterized by
the greatest reduction in aSMA).
3. To evaluate whether the ‘ideal’ GF treatm ent can induce a prolonged
reduction in aSMA expression.
4. To characterize aSMA gene expression in RACs treated with the ‘ideal’
combination of GFs.

1.7 Hypothesis
Porcine RACs treated with a specific combination of growth factors will reduce
aSMA expression, producing a qVIC-like cell type.
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CHAPTER 2:

THE PORCINE RADIAL ARTERY SMOOTH MUSCLE CELL AS A
VALVE INTERSTITIAL CELL SURROGATE FOR HEART VALVE
TISSUE ENGINEERING

2.1 Introduction
Aortic valve disease (AVD) leads to 300,000 surgeries each year, worldwide.1 In
W estern cultures, AVD is typically m anifested in the elderly population, affecting
25% o f people over the age of 65.2 Unfortunately, no therapy exists for AVD and
70% o f diseased valves require surgical intervention. Currently, three valve
replacement options are available to patients: a mechanical valve, a bioprosthetic
or tissue valve, or an allograft or autograft. However, each mqdel presents
com plications that negatively impact the patient’s quality of life. The
thromboem bolic nature, inherent fragility, and eventual structural degeneration of
these models necessitates that other valve replacements be investigated.3 Heart
valve tissue engineering (HVTE) may provide a solution to current valve
lim itations, enabling the creation of a valve that can grow, adapt, and remodel in
response to changes in the valve microenvironment.

Tissue engineering is a relatively new division of organ transplantation that has
emerged over the past 20 years. Tissue engineering is ‘an interdisciplinary field
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that applies principles of engineering and the life sciences toward the
development o f biological substitutes that restore, maintain, and improve the
function o f damaged tissues and organs’.4-6 In general, tissue engineering
involves the isolation of an autologous population of cells; expansion of these
cells in vitro; seeding these cells on to a scaffold, form ing cell-scaffold constructs
(CSCs); culturing the CSCs in vitro using dynamic conditioning; and finally
im plantation.7 Success in HVTE has been limited, although research unveiling
developm ents in heart valve biology and biomechanics have helped to guide
future directions. However, in order to successfully engineer a valve, a
com prehensive understanding o f the aortic valve structure and function must first
be established.

The extraordinary organization o f the aortic valve extracellular matrix (ECM)
facilitates the valve’s unique biomechanical properties. Arranged into three
distinct layers of ECM, each aortic cusp is subdivided into a ventricularis,
spongiosa, and fibrosa.8 The ventricularis is located on the ventricular aspect of
the valve cusp. This layer is dense in radially-oriented elastin fibers, giving the
valve its extensible properties.9 The fibrosa borders the aortic surface o f the
valve and is dense in circum ferentially-oriented collagen fibers, providing this
layer with high tensile strength.9 The spongiosa lies in between the ventricularis
and fibrosa. This layer is dense in glycosaminoglycans, which draw in water
molecules, giving this layer a shock-absorbing and cushioning function. Each
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layer contributes distinct properties to the valve, together facilitating its
successful functioning during each cardiac cycle.

The exceptional three dimensional architecture of the aortic valve is prim arily
m aintained by a population of cells referred to as valve interstitial cells (VICs).10'
13 VICs are a heterogeneous group o f cells that predominantly oscillate between
a quiescent (qVICs) or activated (aVICs) phenotype in the adult valve.13 The
fibroblastic and synthetic nature o f qVICs allows these cells to maintain the
valvular ECM. However, small disturbances in the valve microenvironment can
disrupt this homeostasis. As a result, qVICs are transformed into contractile and
m yofibroblastic aVICs that initiate valve remodeling. Valve remodeling is an
ongoing and tightly regulated process that is very active during development and
progresses towards a homeostatic role in adulthood.14 In order to initiate
rem odeling, VICs increase the synthesis of proteins that can degrade the ECM
(such as m atrix m etalloproteinases (MMPs)), and upregulate còntractile proteins
that facilitate VIC m otility.12,14,15 One protein that is upregulated during valve
remodeling is alpha smooth muscle actin (aSMA).14 Perturbations in the qVIC to
aVIC equilibrium can have severe consequences on valve biology, potentially
leading to valve pathology.

In HVTE, careful consideration must be given towards selecting a cell type that
adequately mimics the functional and phenotypic heterogeneity of the VIC. The
pathological nature o f the qVIC to aVIC imbalance suggests that the cell type
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identified for HVTE must be capable o f adopting a contractile phenotype, yet be
intrinsically fibroblastic. Often, m yofibroblasts have been used as a VIC
substitute for HVTE due to their sim ilarities with the aVIC phenotype.16 Similarly,
smooth muscle cells (SMCs) are analogous to VICs in many ways.17,18 One cell
source that is abundant in SMCs and has already demonstrated its clinical
relevance in coronary artery bypass grafting is the radial artery.

The radial artery has already been explored by our lab as a cell source for HVTE.
Radial artery cells (RACs) collected from the tunica media express high levels of
the contractile protein aSMA in v itro .^ However for the purpose of HVTE, the
expression of aSMA in these cells is too high. The phenotype needs to be
manipulated so that aSMA content is reduced, such that the RACs acquire a
more fibroblastic qVIC-like phenotype. One method that may achieve this
transform ation is by culturing RACs with a combination of growth factors (GFs).

Many studies have examined the responsiveness of SMCs to GF treatm ent.20,21
Previously, our lab has demonstrated that aSMA expression can be reduced in
SMCs isolated from the rat aorta using a triple GF treatm ent consisting of
transform ing growth fa cto r-p i (T, TGF-(31), epidermal growth factor (E, EGF),
and platelet-derived growth factor (P, PDGF).21 These three GFs, along with
basic fibroblast growth factor (F, bFGF) were selected based on their integral
roles in valve form ation during valvulogenesis.22"31 These findings suggest that
aSMA expression in RACs may also be manipulated in a sim ilar fashion, inferring
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that the radial artery may provide an autologous cell source suitable for the
creation o f a bioprosthetic aortic valve. W e propose that treating porcine RACs
with a specific combination of GFs w ill reduce aSMA expression, producing a
more desirable qVIC-like cell source fo r HVTE.
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2.2 Materials and Methods
2.2.1 Radial Artery Cell Isolation
Pig forelim bs were obtained from Canadian Surgical Technologies and Advanced
Robotics (CSTAR, London, ON) and maintained at 4°C until dissection. Radial
arteries were dissected from both left and right forelim bs and collected in one
100 mm2 cell culture dish (Cell Star®, Greiner Bio-one 664160) containing M199
medium (GIBCO 12340) at room tem perature. The arteries were transferred to a
sterile tissue culture hood where they were minced into 1 mm3 sections using a
sterile scalpel. The minced artery pieces were transferred into a 50 ml Falcon
tube (VW R 21008-178) containing 40 ml of filter-sterilized M199 medium
supplemented with 0.08% collagenase type IV (GIBCO 17104-019), 1%
penicillin/streptom ycin (P/S; GIBCO 15140), and 0.25 pg/ml amphotericin B
(Fungizone; GIBCO 15290-018). The artery pieces were incubated in this
solution fo r 24 hours at 37°C. Following incubation, the tubes were centrifuged
at 1250 RPM fo r 5 minutes (Eppendorf, Centrifuge 5416). The supernatant was
aspirated, leaving behind the minced artery pieces. Using sterile forceps, the
artery pieces were distributed equally among three 100 mm2 cell culture dishes.
Each plate received 10 ml of M 199 medium supplemented with 10% fetal bovine
serum (FBS; GIBCO 12483) and 1% P/S, and were stored in a humidified
chamber (HERA Cell 150, Heraeus) at 37°C, 5% CO 2 . The plates were
monitored daily using a light microscope (Olympus CK40) at 10* magnification.
Once sufficient cellular outgrowth had occurred, the artery pieces were removed
using sterile forceps. The cells isolated during this protocol are from here on
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referred to as radial artery cells (RACs). RACs were passaged as necessary,
and stored at -80°C in a solution o f 80% M199 medium, 10% FBS, and 10%
dimethyl sulfoxide (DMSO; Sigma D2650) until required. Each experiment used
RACs between passages 1-3.

2.2.2 Valve Interstitial Cell Isolation
Porcine hearts were obtained from Mount Brydges Abattoir (Mount Brydges, ON)
or Canadian Surgical Technologies and Advanced Robotics (CSTAR, London,
ON), and maintained on ice during travel to the laboratory. Aortic valve cusps
were dissected within one hour of obtaining the hearts, using a scalpel and
forceps. The cusps were stored in phosphate buffered saline (PBS) overnight at
4°C. In a sterile tissue culture hood, the cusps were rinsed three times with filtersterilized PBS supplemented with 0.03% calcium chloride (Fisher Scientific C614), 0.5% amphotericin B, and 1% P/S. Endothelial cells were removed by
incubating the cusps in a solution of sterile TES (2-[(2-hydroxy-1,1-bis
(hydroxym ethyl)ethyl)am ino]ethanesulfonic acid) buffer supplemented with 150
pg/ml collagenase for 20 minutes at 37°C. Cusps were then transferred to 50 ml
Falcon tubes containing 20 ml of 0.125% trypsin-EDTA (GIBCO 25200) and
incubated for 7 minutes at 37°C. The cusps were subsequently vortexed for 1
minute before the surfaces of each cusp were scraped with sterile alcohol swabs
to remove endothelial cells. Cusps were rinsed twice with PBS before being
transferred into 50 ml tubes containing 15 ml of 0.125% trypsin-EDTA. The
cusps were incubated in this solution for 2 minutes at 37°C. The cusps were
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then transferred into a tube containing 20 ml of filter-sterilized PBS, 0.03%
calcium chloride, and 150 pg/ml collagenase, and incubated in this solution for 2
hours at 37°C. Following incubation, the solution was vortexed at maximum
speed fo r 1 minute. The solution was transferred on to a 70 pm nylon cell
strainer (BD Falcon 352350), and the flow through was collected in a 50 ml
Falcon tube. A second strainer was used when the first strainer no longer
produced filtrate. Approxim ately 5 ml of Dulbecco’s Modified Eagle Medium
(DMEM; GIBCO 31053) was used to rinse the contents of the strainers. The
filtrate was collected and centrifuged at 1150 RPM for 7 minutes. Most of the
supernatant was aspirated, leaving a pellet and approximately 1 ml of medium.
The pellet was re-suspended in approxim ately 4 ml of DMEM, supplemented with
10% FBS, 1% P/S, and 1% glutamine. The solution was re-strained into a sterile
35mm2 cell culture dish and returned to the humidified chamber at 37°C, 5%
CO 2 . All three cusps from one aortic valve were cultured together in the same 35
mm2 cell culture dish (Falcon® 353002). Cell growth was monitored daily using
a light m icroscope at 10* magnification. Once visible growth had occurred, the
medium was aspirated and replaced with new DMEM, supplemented with 10%
FBS, 1% P/S, and 1% glutamine. Changing the medium after visible outgrowth
is a precautionary step that may aid in minimizing contamination. The cells
isolated during this protocol are from here on referred to as valve interstitial cells
(VICs). Once the VICs reached approxim ately 90% confluence, the cells were
trypsinized and centrifuged to obtain a pellet. The pellet was re-suspended in a
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solution o f 80% DMEM, 10% FBS, and 10% DMSO and stored at -80°C until
required. Each experiment used VICs between passages 1-2.

2.2.3 Cell Culture
Both VIC and RAC cultures were maintained in ‘culture medium’ in a humidified
incubator at 37°C, 5% CO 2 until confluent. Culture medium consisted of DMEM
supplemented with 10% FBS + 1% P/S + 1% glutamine (GIBCO 10378). Once
confluent, cells were detached from the cell culture plates by incubating them
with 0.25% trypsin-EDTA for 5 minutes at 37°C, 5% CO 2 in a humidified
incubator. DMEM was then added to the cell suspension before it was
centrifuged at 1250 RPM for 5 minutes, and the supernatant discarded. The
pellet was re-suspended in culture medium and the cells were either passaged at
a 1:3 ratio or used for one of the experim ents outlined below.

2.2.4 Growth Factor Treatment
The growth factors (GFs) used in this experiment included epidermal growth
factor (EGF), basic fibroblast growth factor (bFGF), platelet-derived growth factor
(PDGF), or transform ing growth factor-beta 1 (TGF-(51). All GFs were
reconstituted at 10 pg/ml according to the m anufacturer’s instructions (R&D
Systems). GFs were diluted in ‘treatm ent medium’ (consisting o f DMEM
supplemented with 2.5% FBS, 1% P/S, 0.25% glutamine, and 5 pg/ml of Lascorbic acid (Sigma A-4544)) directly prior to cell treatment. The GF treatm ent
medium was changed daily. The cell treatm ent conditions varied slightly
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depending on the experiment, and are summarized in Table 1. Detailed
descriptions o f each experim ent are outlined below (2.2.4.1-4).

2.2.4.1 Effects of growth factors on RAC viability
Approxim ately 10,000 RACs were seeded into wells in a 96-well plate (Falcon®
353072). The cells were allowed to adhere to the plate for 24 hours before they
were serum-starved for another 24 hours using ‘serum -free’ medium (DMEM +
1% P/S). The cells were then treated with increasing doses of EGF, bFGF,
PDGF, or TGF-31. The concentrations selected included 2.5 ng/ml, 5.0 ng/ml,
10 ng/ml, 25 ng/ml, and 50 ng/ml. Untreated RACs (receiving no GFs) served as
negative controls. At the end of the 96-hour treatm ent phase, GF cytotoxicity
was examined using an MTT (3-(4,5-dim ethylthiazol-2-yl)-2,5diphenyltetrazolium ) assay. Each experim ent was performed in triplicate, using
RACs isolated from one animal (n=1).

2.2.4.2 Effects of growth factors on aSMA expression in RACs
Circular coverslips (No.1, 25mm, VWR 48380 080) were placed into 6-well plates
(Falcon® 353046), coated with 250 pi of 0.1% sterile gelatin (BDH Chemicals
B44045) and allowed to air dry overnight. Approxim ately 50,000 RACs or VICs
were seeded on to the coverslips in a volume of 250 pi. The cells were allowed
to adhere fo r approxim ately 2 hours, before culture medium was added to each
well. Once the cells were approxim ately 90% confluent (approximately 72 hours
after cell seeding), they received ‘serum -free’ medium for 24 hours. The cells
were then treated with 10 ng/ml of each GF in combinations of one, two, three, or
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Table 1. Sum m ary o f experim ental design (2.2.4.1-4). This table provides a
summary of: (a) the plates selected fo r each experiment, (b) whether or not the
cells were seeded on to gelatin-coated coverslips, (c) the initial cell seeding
density, (d) the estimated confluence of the cells prior to (e) serum -starvation, (f)
how long the cells received growth factor treatment, and (g) what technique was
used for analysis. Each experim ent varies from the others by at least one
parameter. (IF, immunofluorescence; MTT, 3-(4,5-dim ethylthiazol-2-yl)-2,5diphenyltetrazolium-, PCR, polym erase chain reaction)

m
io
(a)

(b)

(c)

(d)

(e)

(f)

(g)

Plate

Seeded on
gelatincoated
coverslips

Cell
density
/well

Estimated
confluence
prior to
commencing
experiment

Serum, starved
prior to
experiment

Growth
factor
treatment
period

Experiment

Analysis
technique

1

96well
plate

No

10,000

20%

Yes

96 hours

MTT assay

2

6-well
plate

Yes

50,000

90%

Yes

72 hours

IF

3

6-well
plate

Yes

50,000

50%

Yes

72 hours

IF

4

6-well
plate

No

>50,000

90%

Yes

72 hours

Real time
PCR
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four GFs. To sim plify the descriptions o f the GFs used in each treatment; the
abbreviations E (EGF), F (bFGF), P (PDGF), and T (TGF-p1) will be used. The
GF com binations included E, F, P, T, EF, EP, FP, TE, TF, TP, EFP, TEF, TEP,
TFP, and TEFP. Untreated RACs and VICs served as negative and positive
controls, respectively. The cells were treated for 72 hours before the cells were
fixed, stained, and imaged using confocal microscopy. This experiment was
performed in triplicate, using cells isolated from three separate animals (n=3).

2.2.4.3 Effects of growth factors on prolonged aSMA expression in RACs
Coverslips were placed into 6-well plates, coated with 250 pi of 0.1% sterile
gelatin and allowed to air dry overnight. Approxim ately 50,000 RACs or VICs
were seeded on to the coverslips in a volume of 250 pi. The cells were allowed
to adhere for approximately 2 hours, before culture medium was added to each
well. Once at approximately 50% confluence (approxim ately 24 hours after cell
seeding), the cells received ‘serum -free’ medium for the next 24 hours. The cells
were then treated with the GF combinations EFP, TEP, or TEFP. All GFs were
used at a concentration o f 10 ng/ml. Untreated RACs and VICs served as
controls. To assess whether changes in aSMA expression persisted in the
absence of GFs, the entire experim ent was performed in duplicate. The first set
of controls and treatm ent groups received the GF-treatment media for 72 hours.
The second set received GF-treatm ent media for 72 hours, followed by an
additional 72 hours of treatm ent medium without any GFs. At each endpoint, the
cells were fixed; stained fo r aSMA, filam ent actin (F-actin), and nuclei; and
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examined by confocal microscopy. This experim ent was performed in triplicate,
using cells isolated from three separate animals (n=3).

2.2.4.4 Effects of growth factors on aSMA gene expression in RACs
Confluent plates of VICs and RACs were passaged into 6-well plates at a ratio of
1:9. This ratio allowed the cells to reach near confluence in each well
approxim ately 24-48 hours later. A t approxim ately 90% confluence, the cells
were serum-starved for 24 hours. The cells were then treated with 10 ng/ml of
each GF. The GF combinations used in this experiment included EFP, TEP, and
TEFP, while untreated RACs and VICs served as controls. The cells were
treated for 72 hours before RNA was extracted for gene expression analysis
using real tim e polymerase chain reaction (PCR). This experiment was
performed using cells isolated from three separate animals (n=3).

2.2.5 MTT Assay
After 96 hours of treatm ent (2.2.4.1), cell number was estimated using an MTT
Cell Proliferation Assay (Vibrant), according to the m anufacturer’s instructions.
Briefly, a 12 mM MTT solution was prepared by adding 1 ml of sterile PBS to 5
mg o f MTT. The solution was filter-sterilized using a 0.2 pm-pore filter.
Treatm ent media containing the GFs were removed from the cells and replaced
with 100 pi of fresh treatm ent medium (no GFs). Subsequently, 10 pi of the
sterile MTT solution was added to each well and pipetted up and down to mix.
The cells were incubated in this solution for 4 hours at 37°C, 5% CO 2 . The SDS-
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HCI solution was prepared by dissolving 1 g of sodium dodecyl sulfate (SDS;
BioShop SDS 001) into 10 ml of 0.01 M hydrochloric acid (HCI; Caledon 6025-1),
and gently mixing by inversion. This solution was filter-sterilized before 100 pi
was added to each well. Again, the solution was pipetted up and down to mix.
The cells were incubated for another 4 hours at 37°C, 5% CO 2 . The 96-well
plate was removed from the incubator, and the wells gently pipetted, before the
absorbance of each well was read using a spectrophotometer (FluoSTAR
Omega, BMG LabTech). The absorbance of each well was read at a wavelength
o f 570 nm, and the data was analyzed using Omega software (version 1.10).

2.2.6 Immunofluorescence and Confocal Microscopy
Cells (2.2.4.2-3) were fixed and permeabilized using a standardized protocol.
Briefly, the coverslips were rinsed twice with PBS (pre-warmed to 37°C) for 5
minutes each. The cells were then incubated in 10% form alin (Fisher Scientific
F79-1) fo r 1 hour at room temperature in a fume hood, pre-warming the formalin
solution to 37°C prior to use. The form alin solution was discarded and cells were
washed three tim es with PBS at room temperature, at intervals o f 5 minutes.
The cells were then incubated with 0.05% Triton-X-100 (BDH Chemicals
R06433) in PBS for 5 minutes at room temperature. The cells were rinsed again
with PBS and stored at 4°C until staining.

Prior to cell staining, the cells were blocked for 30 minutes at room temperature
with serum-free protein block (Dako X0909). The cells were stained with Cy3-
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conjugated anti-aSM A (Sigma C6198) for 1 hour, AlexaFluor® 488 Phalloidin
(Invitrogen A12379) for 20 minutes, and Hoecsht (Sigma B2261) for 5 minutes.
Both the aSMA and AlexaFluor® 488 phalloidin antibodies were diluted in
Antibody diluent (Dako S0809) at dilutions of 1:200 and 3:40, respectively. A
saturated ethanolic solution o f Hoecsht was diluted in PBS at a dilution of 1:200.
Each staining solution was incubated at room temperature, and the incubations
were separated by three consecutive 5 minute washes with PBS. After the final
washes, the cells were mounted on standard microscopy slides (VWR 48312002) using Fluorescent Mounting medium (Dako S3023).

Cells were imaged on a Zeiss LSM410 confocal microscope (Carl Zeiss) at 40x
m agnification, using water immersion. Z-stacks (1 pm sections) were taken for
the entirety of the cell thickness and maximum 3D projections were calculated.
Five fields of view were taken for each slide, including one central image and four
images around the periphery, when possible. The brightness and contrast of
each image were adjusted so that one pixel of saturation was obtained per field
of view. Cells were counted positive if approximately 25% or greater of the cell
stained for aSMA. The total number of cells per field of view was counted by
quantifying the nuclei per frame, using F-actin to verify that all cells were
included. All treatm ents were blinded for quantification.
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2.2.7 Real Time Polymerase Chain Reaction
RNA was isolated from RACs using the RNeasy® Mini Kit (Qiagen 74106), and
from VICs using TRIzol® Reagent (Invitrogen 15596-026) according to the
m anufacturer’s instructions. The RNA was quantified using the Nanodrop 2000
(Thermo Fisher Scientific). The RNA samples were run on a 1% agarose
(Bethesda Research Laboratories (BRL) 5510UB) gel to assess the sample
integrity. Each sample was then diluted to a concentration of 100 ng/pl before
100 ng was used to synthesize cDNA using qScript™ cDNA SuperMix (Quanta
BioSciences, Inc. 95048-100). The cDNA was quantified using a Nanodrop
2000, diluted to 400 ng/pl, and stored at -80°C until use.

Prim er sets for porcine glyceraldehyde 3-phosphate dehydrogenase (GAPDH),
and aSMA were generated (sequence and prim er data can be found in Appendix
A). Prim er sets were amplified at their recommended annealing temperatures
using PCR, and the resulting DNA was purified. A standard curve was generated
for each prim er set using the purified DNA sample, and increasing the copy
number of DNA in each sample on a logarithm ic scale. Only standards 1 through
7 (10° through 106) were used for real time-PCR as the sensitivity o f PerfeCTa™
SYBR® Green SuperMix (Quanta BioSciences, Inc. 95054-500) does not exceed
106 copies. The standards were run on the Rotor-Gene RG-3000 (Corbett
Research) using Rotor-Gene 6 software for data collection and analysis. The
samples were run using the following protocol: 3 min initialization at 95°C; 45
cycles of (i) 95°C denaturation (12 s), (ii) annealing temperature (35 s), and (iii)
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72°C elongation (30 s); followed by a final elongation at 72°C fo r 5-15 minutes.
Annealing temperatures vary by primer, and a detailed summary can be found in
Appendix A. A standard curve with an efficiency value between 0.9-1.1 and an
R2 value greater than 0.99, was considered acceptable.

The RAC and VIC samples were run with each primer set at the predetermined
annealing temperature. The samples were run in triplicate, each reaction using
800 ng o f cDNA.

Ct (cycle threshold) values were produced for each sample,

and reflect the cycle at which the samples pass a pre-established ‘threshold’

Ct values for the gene of interest were normalized
to GAPDH, which provided an internal control. This calculation produced the ACt
values. All of the ACt values for the control RAC group were then averaged
together, producing ACtavgc- The ACtaVgc was then subtracted from the ACt
values fo r each sample, yielding the AACt values to be used fo r analysis. In
(num ber o f DNA copies). The

order to measure fold change, the equation 2_AACt was used. These values
reflect a fold change in gene expression that has been normalized to the
housekeeping gene GAPDH as well as the untreated RAC control group.

2.2.8 Statistical Analysis
All samples were analyzed using a one-way analysis o f variance (ANOVA),
followed by a Tukey’s post hoc test. Values are expressed as a mean ± standard
error of the mean (SEM). Statistical analysis was performed using GraphPad
Prism 5 software. A p-value less than 0.05 was considered significant.
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2.3 Results
2.3.1 Growth factors tested are not cytotoxic to RACs
RACs were treated daily with a range of doses (from 2.5-50 ng/ml) of EGF,
bFGF, PDGF, or TGF-31 for 96 hours. Untreated RACs served as controls.
Relative cell num ber was then determined using the MTT assay. RACs tolerate
individual doses of EGF, bFGF, PDGF, and TGF-31 up to 50 ng/ml relatively well
(Figure 6). Examining the GFs individually, it appears that bFGF may be
stim ulating proliferation of the RACs; however, this trend cannot be confirmed as
no statistical analysis was performed on this data (n=1).

2.3.2 EFP treatment reduces aSMA expression in RACs
Representative images of the effects o f EGF (E), bFGF (F), PDGF (P), and/or
TGF-31 (T) on aSMA expression in RACs are shown in Figure 7. RACs were
treated with the GFs individually (ii), or with a combination of two GFs (iii), three
GFs (iv), or four GFs (v) for 72 hours. Untreated RACs and VICs (i) served as
controls. The cells were stained for F-actin in green, aSMA in red, and nuclei in
blue. aSMA serves as a m arker of cell transdifferentiation, as the cells are
shifted from the SMC to m yofibroblast phenotype. A decrease in aSMA
expression indicates that the RACs have progressed towards a qVIC-like
phenotype.

Both untreated RACs and VICs show high levels o f aSMA expression (Figure 7i).
W ithin the groups o f RACs treated with only one GF, aSMA expression was
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Figure 6. The dose-response re la tio n s h ip fo r RACs trea te d w ith EGF, bFGF,
PDGF, and TGF-01 fo r 96 hours. RACs were treated with 2.5 ng/ml, 5.0 ng/ml,
10 ng/ml, 25 ng/ml, or 50 ng/ml of EGF (red square), bFGF (green triangle),
PDGF (purple cross), or TGF-01 (blue circle) for 96 hours, before mitochondrial
viability was quantified using an MTT assay. Untreated RACs served as a
control (black line). Absorbance was read at 570 nm and is directly proportional
to the number of viable mitochondria in a given sample. The RACs appear to
tolerate all concentrations of each GF well, as indicated by little negative
variance from the untreated controls. Furthermore, bFGF appears to exhibit a
positive effect on bell growth, diverging from the absorbance values o f other GFs
at approxim ately 10 ng/ml.

(EGF, epiderm al growth factor, bFGF, basic fibroblastic growth factor, PDGF,
platelet-derived growth factor, TGF-(31, transform ing growth factor-beta 1\ RAC,
radial artery cell', MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-, GF,
growth factor, ng, nanogram-, ml, millileter, nm, nanometer)
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F igure 7. R epresentative im ages o f aSM A e xp re ssio n in RACs treated w ith
co m b in a tio n s o f g ro w th fa c to rs fo r 72 ho urs. RACs were treated with EGF
(E), bFGF (F), PDGF (P), and/or TGF-(51 (T) in com binations of one, two, three,
or four GFs. The treatm ent groups included E, F, P, T, EF, EP, FP, TE, TF, TP,
EFP, TEF, TEP, TFP, and TEFP. All GFs were used at a concentration of 10
ng/ml. Untreated RACs and VICs were included as controls. The cells were
cultured on gelatin-coated coverslips for 72 hours, before they were fixed and
stained for F-actin (green), aSMA (red), and nuclei (blue). The cells were imaged
using a Zeiss LSM410 confocal microscope (Carl Zeiss) at 40x magnification,
using water immersion. Representative maximum projections o f the (i) untreated
RAC and VIC controls, (ii) single GF combinations, (iii) double GF combinations,
(iv) triple GF combinations, and (v) quadruple GF com bination are presented. Factin, aSMA, and nuclei staining can be visualized separately or merged
together. RACs treated with E, F, and/or P (ii-iv) show a reduction in aSMA
expression compared to the untreated controls. All treatm ents were performed in
triplicate, using cells isolated from three separate anim als (n=3). The arrows
point to an aSMA-positive cell. The arrowhead points to a cell with a rounded
morphology. Scale bar = 50 pm.

(EGF, E, epiderm al growthJactor, bFGF, F, basic fibroblastic growth factor,
PDGF, P, platelet-derived growth factor, TGF-P1, T, transform ing growth factorbeta 1\ RAC, radial artery cell; VIC, valve interstitial cell', GF, growth factor, Factin, filam entous actin', aSMA, alpha-smooth muscle actin', ng, nanogram', ml,
m illileter)
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significantly reduced in RACs treated with E, F, or P (Figures 7ii and 8). T had
no effect on aSMA expression in RACs. A sim ilar trend was observed in all
RACs treated with T in combination with one or two additional GFs. RACs
treated with TE, TF, TP, TEF, TEP, or TFP showed no change in the number of
cells that stained positively for aSMA (Figures 7iii-iv and 8). In contrast, aSMA
expression in RACs treated with EF, EP, or FP was significantly reduced (Figure
7iii). EFP treatm ent further reduced to approxim ately 25% of the aSMA
expression seen in the untreated RAC controls (Figures 7vi and 8). The
com bination of E, F, and P appears to be having a synergistic effect, reducing
aSM A expression greater than each GF could alone. Interestingly, a
com bination of all four GFs in the TEFP treatm ent reduced aSMA expression to a
level intermediate of the untreated RACs and those treated with EFP (Figure 7v
and 8). These findings are supported by aSMA quantification, presented in
Figure 8.

Furthermore, RACs treated with T in combination with any other number of GFs
exhibited a more contractile phenotype in vitro. In most cases, these cells
form ed dense aggregates within 1-2 days o f treatm ent. This property also made
these cells very difficult to fix, as the adherence o f these cells to the gelatincoated coverslips was compromised. Additionally, the cell size in these treated
groups appeared to be larger and more comparable to the untreated RACs when
compared to cells treated with a GF combination that did not include T. Although
these features have not been quantified, the contractile phenotype of RACs
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F igure 8. Q u a n tifica tio n o f oSM A exp re ssio n in RACs trea te d w ith
co m b in a tio n s o f g ro w th fa c to rs fo r 72 ho urs. RACs were treated with EGF
(E), bFGF (F), PDGF (P), and/or TGF-(31 (T) in combinations o f one, two, three,
or four GFs. The treatm ent groups included E, F, P, T, EF, EP, FP, TE, TF, TP,
EFP, TEF, TEP, TFP, and TEFP. All GFs were used at a concentration of 10
ng/ml. Untreated RACs and VICs were included as controls. The cells were
cultured on gelatin-coated coverslips for 72 hours, before they were fixed and
stained for F-actin, aSMA, and nuclei. The cells were imaged using a Zeiss
LSM410 confocal microscope (Carl Zeiss). aSMA expression was quantified by
counting the number o f aSMA-positive cells per fram e and representing this
value as a percentage o f the total number o f cells per fram e. RACs treated with
E, F, P, EF, EP, FP, or EFP significantly reduced aSMA expression compared to
the untreated controls. An asterisk (*) denotes a significant change from the
untreated RAC control ( p<0.05). All values are represented as the mean ± SEM.
All treatm ents were performed in triplicate, using cells isolated from three
separate animals (n=3).

(EGF, E, epiderm al growth factor, bFGF, F, basic fibroblastic growth factor,
PDGF, P, platelet-derived growth factor, TGF-01, T, transform ing growth factorbeta 7; RAC, radial artery cell] VIC, valve interstitial cell] GF, growth factor, Factin, filam entous actin', aSMA, alpha-smooth muscle actin', ng, nanogram] ml,
m illileter)
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treated with T, TE, TF, TP, TEF, TEP, or TEFP can be seen in Figures 7ii-v.
These cells exhibit an elongated morphology, as well as stress fiber formation
where aSM A and F-actin are colocalized. In contrast, RACs treated with E, F, P,
EF, EP, FP, or EFP exhibited either an elongated or rounded morphology (Figure
7ii-iv). In these groups, aSMA expression appears to colocalize with the
elongated phenotype and is drastically reduced in the cells that exhibit a rounded
morphology.

2.3.3 EFP induces a stable change in aSMA protein expression in RACs
To assess whether the GF-induced changes in aSMA expression are maintained,
RACs were cultured with GFs for 72 hours (72+) followed by a 72 hour GF
absence (72+/-). Three GF treatm ent groups were chosen. These groups were
selected based on the data presented in Figures 7 and 8. EFP, TEP, and TEFPtreated RACs represent a range of aSMA expression; reflecting low, medium,
and high levels o f aSMA expression, respectively. Untreated RACs and VICs
were included as controls. Cells were stained for F-actin (green), aSMA (red),
and nuclei (blue).

aSMA expression can be seen qualitatively in Figures 9A and B, and
quantitatively (expressed as % aSMA-positive cells) in Figure 10. Figure 9A
shows a com posite of F-actin, aSMA, and nuclei staining following 72 hours of
GF therapy (72+), and also following 72 hours of GF withdrawal (72+/-). Figure
9B highlights aSMA expression by excluding F-actin staining at both tim e points,

73

I
\i

i

I
{
i

L

\

\

F igure 9. R epresentative im ages o f th e e ffe cts o f 72 h o u rs o f GF
w ith d ra w a l on aSM A exp re ssio n in RACs. RACs were treated for (i) 72 hours
(72+) with the GF combinations EFP, TEP, or TEFP, followed by an additional (ii)
72 hours of GF withdrawal (72+/-). All GFs were used at a concentration of 10
ng/ml. Untreated RACs and VICs were included as negative and positive
controls, respectively at both tim e points. The cells were fixed and stained fo r Factin (green), aSMA (red), and nuclei (blue); and imaged using a confocal
microscope. Representative maximum projections o f the controls and treatm ent
groups at the (i) 72+ and (ii) 72+/- time points are presented as (A) a merged
image, or (B) a composite of aSMA and nuclei staining. Both untreated VICs and
EFP-treated RACs showed a reduction in aSMA expression at both the 72+ and
72+/- time points. All treatm ents were performed in triplicate, using cells isolated
from three separate animals (n=3). The arrows point to an aSMA-positive cell.
The arrowhead points to a cell with a rounded morphology. Scale bar = 50 pm.

(Untr, untreated; EFP, EGF+bFGF+PDGF; TEP, TGF-fi 1+EGF+PDGF] TEFP,
TGF-p1+EGF+bFGF+PDGF; RAC, radial artery cell] VIC, valve interstitial cell]
GF, growth factor, F-actin, filam entous actin', aSMA, alpha-smooth m uscle actin',
ng, nanogram] ml, m illileter, 72+, 72 hours o fG F treatment, 72+1-, 72 hours o f
GF treatm ent followed by 72 hours o f GF withdrawal)
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Figure 10. Quantification of the effects of 72 hours of GF withdrawal on
oSMA expression in RACs. RACs were treated fo r (i) 72 hours (72+) with the
GF combinations EFP, TEP, or TEFP, followed by an additional (ii) 72 hours of
GF withdrawal (72+/-). All GFs were used at a concentration o f 10 ng/ml.
Untreated RACs and VICs were included as negative and positive controls,
respectively, at both time points. The cells were fixed and stained for F-actin,
aSMA, and nuclei. Cells were imaged using a Zeiss LSM410 confocal
microscope. aSMA expression was quantified by counting the number of aSMApositive cells per fram e and representing this value as a percentage o f the total
number o f cells per frame. Both untreated VICs and EFP-treated RACs showed
a significant decrease in aSMA expression from the untreated controls at both
the 72+ (white bars) and 72+/- (black bars) tim e points. An asterisk (*) denotes a
significant difference from the untreated RAC control at 72+ (p<0.05), while a
double cross ( t) denotes a significant difference from the untreated RAC control
at 72+/- (p<0.05). All values are represented as the mean ± SEM. All treatments
were performed in triplicate, using cells isolated from three separate animals
(n=3).

(Untr, untreated; EFP, EGF+bFGF+PDGF; TEP, TGF-01+EGF+PDGF; TEFP,
TGF-p 1+EGF+bFGF+PDGF) RAC, radial artery cell) VIC, valve interstitial cell)
GF, growth factor, F-actin, filam entous actin', aSMA, alpha-smooth muscle actin',
ng, nanogram) ml, m illileter, 72+, 72 hours o fG F treatment, 72+1-, 72 hours o f
GF treatm ent followed by 72 hours o f GF withdrawal)
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enabling the easy qualification of cells that do not express aSMA (nuclei in the
absence o f red staining). At the 72+ tim e point, aSMA expression in the
untreated RAC controls was significantly greater than in the untreated VICs
(Figure 9Bi). This trend was maintained at the 72+/- time point; aSMA
expression in the untreated RAC controls remained significantly elevated in
comparison to the untreated VICs (Figure 9Bii). In the treatm ent groups, aSMA
expression in both TEP-treated and TEFP-treated RACs showed no significant
difference from the untreated controls at the 72+ tim e point (Figure 9Bi). An
additional 72 hours of GF withdrawal did not alter aSMA expression in these
groups, as they remained statistically insignificant from the untreated RAC
controls (Figure 9Bii). However, the aSMA expression in RACs treated with EFP
was significantly reduced compared to the untreated RAC controls at both the
72+ (Figure 9Bi) and 72+/- (Figure 9Bii) tim e points. Furthermore, the EFPtreated RACs and untreated VICs showed comparable levels of aSMA
expression at both time points. A quantification of aSMA expression confirms
these observations (Figure 10).

RACs treated with EFP at 72+ (Figure 9Ai) exhibited a mixture of elongated and
rounded morphologies, sim ilar to the VICs at both tim e points (Figure 9Ai-ii).
However, following GF withdrawal for 72 hours, the EFP-treated RACs reverted
back to a more elongated (and contractile) appearance, despite maintaining an
absence o f aSMA staining (Figure 9Aii). In addition, the cell size varies from the
untreated RACs and VICs to the EFP-, TEP-, and TEFP-treated RACs (Figure
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9Ai). The RACs that maintained a high expression of aSMA (untreated, TEP-,
and TEFP-treated RACs) appeared to have larger nuclei than the cells with lower
aSMA expression (EFP-treated RACs and untreated VICs). However, in the
absence o f GFs for 72 hours, nuclei of the EFP-treated RACs appeared to
become more sim ilar in size to the untreated RACs (Figure 9Aii).

2.3.4 EFP significantly reduces aSMA gene expression in RACs
RNA from RACs grown on plastic culture dishes, and treated with EFP, TEP, or
TEFP fo r 72 hours was collected and quantified using real time PCR. The RNA
from both untreated RACs and VICs served as negative and positive controls,
respectively. aSMA expression was normalized to GAPDH, which served as an
internal control. The 2'LACX values were used for analysis, and represent the fold
change in gene expression, when normalized to both GAPDH and aSMA gene
expression in the untreated RACs (a more detailed description can be found in
M aterials and Methods 2.2.7).

In comparison to the untreated RAC controls, aSMA gene expression in
untreated VICs was significantly greater (relative to GAPDH), almost doubling
aSMA gene expression in the untreated RACs (Figure 11). In contrast, aSMA
gene expression in EFP-treated RACs was significantly reduced to less than 1%
of the untreated RAC controls. RACs treated with TEP or TEFP also showed a
significant reduction in aSMA gene expression in comparison to the untreated
RAC control, although not to the same extent as the EFP-treated RACs.
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9Ai). The RACs that maintained a high expression o f aSMA (untreated, TEP-,
and TEFP-treated RACs) appeared to have larger nuclei than the cells with lower
aSMA expression (EFP-treated RACs and untreated VICs). However, in the
absence o f GFs for 72 hours, nuclei of the EFP-treated RACs appeared to
become more sim ilar in size to the untreated RACs (Figure 9Aii).

2.3.4 EFP significantly reduces aSMA gene expression in RACs
RNA from RACs grown on plastic culture dishes, and treated with EFP, TEP, or
TEFP fo r 72 hours was collected and quantified using real time PCR. The RNA
from both untreated RACs and VICs served as negative and positive controls,
respectively. aSMA expression was normalized to GAPDH, which served as an
internal control. The 2'MCt values were used for analysis, and represent the fold
change in gene expression, when normalized to both GAPDH and aSMA gene
expression in the untreated RACs (a more detailed description can be found in
M aterials and Methods 2.2.7).

In comparison to the untreated RAC controls, aSMA gene expression in
untreated VICs was significantly greater (relative to GAPDH), almost doubling
aSMA gene expression in the untreated RACs (Figure 11). In contrast, aSMA
gene expression in EFP-treated RACs was significantly reduced to less than 1%
of the untreated RAC controls. RACs treated with TEP or TEFP also showed a
significant reduction in aSMA gene expression in comparison to the untreated
RAC control, although not to the same extent as the EFP-treated RACs.
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F igure 11. Fold change in norm alized aSM A gene e xp re ssio n in RACs
fo llo w in g 72 hours o f GF trea tm e nt. RACs were treated with the GF
combinations EFP, TEP, or TEFP fo r 72 hours, before RNA was collected and
aSMA gene expression was quantified using real time PCR. All GFs were used
at a concentration of 10 ng/ml. Untreated RACs and VICs were included as
controls. aSMA gene expression was normalized to GAPDH, which served as an
internal control. The 2_AACt values were used for analysis, and represent the fold
change in gene expression, when normalized to both GAPDH and aSMA gene
expression in the untreated RACs. In comparison to the untreated RAC controls,
aSMA gene expression was significantly elevated in the untreated VICs.
Conversely, aSMA gene expression was reduced approxim ately 100-fold in
RACs treated with EFP. An asterisk (*) denotes a significant difference from the
untreated RAC control (p<0.05). All values are represented as the mean ± SEM.
All treatm ents were performed using cells isolated from three separate animals
(n=3).

(Untr, untreated; EFP, EGF+bFGF+PDGF] TEP, TGF-01+EGF+PDGF] TEFP,
TGF-p 1+EGF+bFGF+PDGF\ RAC, radial artery cell] VIC, valve interstitial cell]
GF, growth factor, Ct, cycle threshold] aSMA, alpha-smooth m uscle actin]
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; ng, nanogram] ml,
m illileter)
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2.4 Discussion
This is the first description o f promoting a reduction in alpha-smooth muscle actin
(aSMA) expression in radial artery cells (RACs) using a combination of epidermal
growth factor (E, EGF), basic fibroblast growth factor (F, bFGF) and plateletderived growth factor (P, PDGF). W e suggest that treating RACs with EFP
produces a heterogeneous population o f cells, sim ilar to valve interstitial cells
(VICs).

To assess whether growth factors (GFs) could be used to transform RACs into a
viable VIC surrogate, we first established how RACs responded to the GFs in
vitro. GF concentrations ranging from 2.5 ng/ml to 50 ng/ml exhibited no
negative effects on mitochondrial viability. We opted to use, as this
concentration that is at least 10-fold the EC50 values of each GF. Previous
studies in our lab successfully used GFs at 10 ng/ml to reduce aSMA expression
\

in rat aortic smooth muscle cells (SMCs).21 Based on these findings, we opted to
use 10 ng/ml as our effective concentration for all subsequent experiments. In
addition, a concentration o f 10 ng/ml is at least 10-fold the EC50 values of each
GF, and should ensure that GF receptor pathways are being activated. Some
other investigators report that GFs, especially transforming growth factor-beta 1
(T, TGF-31), exhibit effects on cell differentiation at much lower concentrations,
and that these effects can vary with increasing doses.20
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To identify the most effective combination o f growth factors that promote the
transform ation o f RACs into a quiescent VIC (qVIC)-like phenotype, RACs were
treated with combinations o f one, two, three, or four GFs for 72 hours, and
imaged using confocal microscopy. aSMA expression was used as a marker of
cell transdifferentiation from the SMC phenotype. O f all 15 treatments, EFP led
to the greatest reduction in aSMA expression, restricting expression to
approxim ately 20% of the cells. EFP led to a greater reduction than the single or
paired combinations of E, F and P, although not to a significant level. It appears
that the three GFs are acting together in an additive fashion to reduce aSMA,
greater than either GF could alone. This finding suggests that this triple GF
therapy is somehow capitalizing on inherent SMC plasticity, forcing these cells
towards a synthetic phenotype.

Among the other GF treatments, specifically the TEP treatment, we observed
opposite effects on aSMA expression than was shown in another animal model.
Previously, our lab demonstrated that TEP-treated cells showed the greatest
reduction in aSMA expression in rat aortic SMCs.21 However, this study did not
evaluate the effects o f EFP on aSMA expression. In addition, the cells in our
study were cultured on gelatin-coated coverslips. Discrepancies in the effects of
the various GF treatments on aSMA expression may be a product of the
com pliant gelatin matrix, or sim ply reflect the differences in animal and arterial
models. In the current experiment, no change in aSMA expression was
observed with the TEP treatment, or with any other treatm ent containing TGF-01
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in combination with one or two other GFs. Although inconsistent with the rat
model, these findings are consistent with the literature concerning an induction in
aSMA expression and promotion o f a m yofibroblast phenotype by TGF-31 in
SMCs.32,33 Furthermore, an interesting finding was that the TEFP-treated RACs
in our model exhibited an intermediate level of aSMA protein expression. It is
possible that the combination o f EFP partially represses TGF - 3 1 -induced
increases in aSMA. It would be interesting to explore this finding further.

A fter identifying our ‘ideal’ GF treatm ent, it was im portant to establish whether 72
hours o f EFP treatment was sufficient to induce a prolonged reduction in aSMA
expression in RACs. W e were hopeful that the EFP treatm ent could minimize
RAC plasticity, confining their phenotypic expression to synthetic or semicontractile states that would more adequately mimic the qVIC and activated VIC
(aVIC), respectively. Interestingly, we found that despite 72 hours of GF
withdrawal, EFP-treated RACs maintained a low expression o f aSMA. Moreover,
the level o f aSM A expression in the EFP-treated RACs paralleled the expression
profile in the untreated VICs. These findings indicate that EFP can induce a
long-term change in aSMA expression, m aintaining a qVIC-like phenotype even
in the absence o f GF treatment.

Furthermore, we discovered that aSMA gene expression in EFP-treated RACs
reflected the change in aSMA protein expression. EFP treatm ent reduced aSMA
gene expression to 1% o f the untreated RAC controls after 72 hours of GF
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treatment. Unexpectedly, the TEP and TEFP treatments also showed a
significant reduction in aSMA gene expression in comparison to the untreated
controls. These findings suggest that the GF treatm ents are strongly impacting
gene expression, and that either a delay exists in translating these changes into
protein expression or more likely, that our method o f measuring aSMA protein
expression is not as sensitive as real tim e PCR. One molecule that may be
involved in modifying gene expression in response to the GF treatm ents is serum
response factor (SRF). SRF has been implicated in the regulation of SMC
plasticity, altering histone and chromatin structure through epigenetic
m odifications.34 Identifying the intracellular signaling cascade that is mediating
changes in aSMA gene and protein expression in response to EFP treatm ent will
help us to understand the full potential o f this treatment.

Interestingly, we found that aSMA protein and gene expression in the untreated
VIC controls was inconsistent throughout this study. aSMA protein expression in
VICs is significantly elevated when compared to untreated RACs in Figure 8,
while it is significantly reduced in comparison to the untreated RACs in Figure 10.
Moreover, aSMA gene expression in VICs nearly doubled that in the untreated
RACs (Figure 11). It is possible that we have unknowingly promoted the
development o f either the qVIC or aVIC using slight changes in culture
conditions.
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Several studies on VI Cs have revealed that in vitro, these cells adopt either a
fibroblastic or m yofibroblastic phenotype, likely corresponding to the qVIC or
aVIC phenotypes, respectively.10,11 Elevated aSMA expression has been
reported in vitro when using s tiff m atrices.35 Opposite to what Lui et al. had
predicted,13 increased cell density and passage number are inversely
proportional to aSMA expression.36,37 In the present two experiments in which
aSMA expression was elevated, VICs were cultured at high densities
(approxim ately 90% confluence). In addition, VICs cultured for gene expression
analysis were cultured on plastic culture plates, which may be providing a less
com pliant matrix than gelatin. It is possible that we maintained the qVIC
phenotype in the experim ent that witnessed decreased aSMA expression in
untreated VICs by seeding these cells on a relatively ‘soft’ matrix. An analysis of
aSM A gene expression using RNA isolated from VICs cultured on gelatin-coated
coverslips could help confirm this theory.

One challenge in HVTE has been identifying a cell type that mimics the
heterogeneity o f VICs. Both m yofibroblasts and stem cells have shown promise
in HVTE, yet neither cell type is ideal.16,38,39 M yofibroblasts are more sim ilar to
aVICs than qVICs, which does not reflect the balance of these phenotypes in the
normal adult aortic valve and may result in valve pathology as a result of excess
activation o f remodeling pathways. Conversely, stem cells isolated from bone
marrow have a very low yield, representing only a fraction of the aspirated cell
population.40 A cell type that is clinically accessible, and accurately represents
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the adult aortic valve VIC population has yet to be identified. Here, we
dem onstrate the usefulness of the radial artery as a HVTE cell source. In only 72
hours, a combination of EGF, bFGF, and PDGF (EFP) can reduce aSMA
expression in RACs, promoting a VIC-like cell type that may be suitable for future
HVTE efforts.
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CHAPTER 3: SUMMARY

3.1. Conclusions
Previously, cells used as a VIC substitute in HVTE consisted exclusively of
m yofibroblasts, SMCs, or stem cells. Although both smooth muscle cells and
stem cells have demonstrated their effectiveness in vitro and when implanted into
the pulmonary position of an ovine model, the ECM production and tensile
strength o f these conduits are insufficient to succeed in the aortic position.1'2
One possible explanation for the limited progress in aortic HVTE is the use o f a
cell type that is too dissim ilar from adult aortic VICs.

In this study, we explored the use of SMCs as a cell source for HVTE, with the
intent o f promoting a qVIC phenotype using a combination o f growth factors. In
the healthy adult aortic valve, qVICs are the predominant cell type and exhibit
\

low levels o f aSMA expression.3 In contrast, the aVIC phenotype, as well as
valve rem odeling and disease, are all commonly associated with high levels of
aSMA.3"6 These findings indicate that aSMA is inversely correlated to the health
o f the aortic valve, which may provide an important consideration for HVTE that
has previously been overlooked. Here, we demonstrate that the triple growth
factor treatm ent EFP can induce a prolonged modulation in SMC phenotype,
causing the SMCs to become phenotypically sim ilar to the aortic qVIC.
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An added benefit of our present technique was the cell source we elected to use,
the radial artery. In contrast to the carotid artery, bone marrow, umbilical cord, or
any other cell source that has been previously investigated for HVTE, the radial
artery is both abundant in SMCs and readily accessible.7

However, in order to determine whether the EFP-treated RACs will thrive as a
VIC substitute, this cell type needs to be further characterized. First, we need to
assess whether EFP-treated RACs will adhere to and infiltrate a scaffold,
successfully form ing cell scaffold constructs (CSCs). An interesting extension
that our lab wishes to investigate is the time-dependent release of EGF, bFGF,
and PDGF from an electrospun scaffold consisting of collagen fibers.8 A
sustained release of these GFs will allow the inherently migratory SMCs to first
infiltrate the collagen fiber scaffold, before they are slowly converted into a more
qVIC-like phenotype. However, it would still be important to assess the
proliferative and m igratory potential of EFP-treated RACs as these processes are
im portant in normal valve maintenance and remodeling.

It would be interesting to determine how EFP-treated RACs interact with other
cells in the valve environment, particularly endothelial cells. In the native aortic
valve, the interplay that exists between valve endothelial cells (VECs) and VICs
is critical to normal valve function.9 VECs lining the valve cusps provide a nonthrombogenic layer, while also participating as key moderators in transducing
extracellular signals to VIC s.10 Previously, our lab has investigated the
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interaction between RACs and an endothelial cell layer, demonstrating that
endothelial cells inhibit the outward proliferation of RACs and prevent any
increases in cell thickness.11 We would like to determine whether sim ilar trends
occur when seeding a confluent layer o f endothelial cells on top o f EFP-treated
RACs.

Another param eter that needs to be assessed is how the CSCs would respond to
dynamic conditioning. Using pulsatile flow duplicator systems (‘bioreactors')
and/or cyclic flexure, dynamic conditioning simulates the biomechanical valve
environm ent in vitro. Many studies advocate the beneficial effects of
biomechanical conditioning on tissue formation and extracellular matrix
organization in tissue engineered heart valves (TEHV).12'15

O ther in vivo conditions to explore include biochemical cues, such as oxygen
tensions. The aortic valve is largely avascular,16,17 and therefore it would be
im portant to assess how EFP-treated RACs respond to a low oxygen
environment. Some HVTE studies have already explored this avenue, finding
that low oxygen (7% ) can promote increased ECM synthesis.18 Ultimately, the
potential of EFP-treated RACs for HVTE would be assessed in an animal model,
implanting the CSCs in the aortic valve position for a prolonged period of time.
These studies would provide a more conclusive indication as to how this therapy
would fare in humans.
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The findings in this study are promising fo r future HVTE efforts. We have
demonstrated that the radial artery provides an autologous cell source, abundant
in smooth muscle cells that can be transform ed into qVIC-like cells by the triple
GF com bination, EFP. In the future, assessing the effects of a collection of
biochem ical, biomechanical, and cellular cues native to the heart valve
environm ent will elucidate how EFP-treated RACs w ill respond as the cellular
constituent o f a TEHV.
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APPENDIX A

Prim er Sequences

Gene

GAPDH
(porcine)

Product
Size

Annealing
Temperature

86 bp

55°C

165 bp

61 °C

Sense (forward):
TGT ACC ACC AAC TGC TTG GC
A nti (reverse):
GCA TGG ACT GTG GTC ATG AG

aSMA
(porcine)

Sense (forward):
GAC TGG CAT TGT GCT GGA CT
A n ti (reverse):
GTG GTC ACG AAG GAG TAG CC

GAPDH, glyceraldehyde 3-phosphate dehydrogenase
aSMA, alpha-smooth muscle actin
bp, base pairs

